Provider of prescription drugs for the treatment of rare central nervous system and inflammatory disorders. The company's primary drug is H.P. Acthar Gel (repository corticotropin injection), an injectable drug that is approved by the U.S. Food and Drug Administration (FDA) for the treatment of various diseases and disorders. The company also markets Doral (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. H.P. Acthar Gel H.P. Acthar Gel is a natural source, highly purified preparation of the adrenal corticotropin hormone (ACTH).